Background-We sought to compare maximal left ventricular (LV) wall thickness (WT) measurements as obtained by routine clinical practice between echocardiography and cardiac magnetic resonance (CMR) and document causes of discrepancy. Methods and Results-One-hundred and ninety-five patients with hypertrophic cardiomyopathy (median age, 52.8±15.1 years) who underwent echocardiography and CMR imaging within 6 months (median, 41 days; interquartile range, 16-97 days) were included. LVWT was assessed in parasternal long and short axis by 2-dimensional echocardiography and in short axis by CMR. By Bland-Altman plot, mean maximal LVWT difference between echocardiography and CMR was 0.5 mm (95% confidence interval, −6.9, 7.8) with equal distribution of discrepancy along the full range of LVWT. Ninety-seven patients (49.7%) were identified to have intermodal measurement discrepancies ≥10%. In 7 patients (7.2%), reported measurement by CMR was inaccurate because of interpretation error. In 90 patients (92.8%), echocardiography underestimated (n=32; 33.0%) or overestimated (n=58; 59.8%) maximal LVWT. Underestimation was because of focal LV hypertrophy (n=10; 10.3%) or poor acoustic windows (n=22; 22.7%) while overestimation resulted from inclusion of right ventricular myocardium (n=37; 38.1%), LV trabeculations (n=5; 5.2%), papillary muscle (n=3; 3.1%), and apical-septal bundle (n=1; 1.0%), as well as imaging plane obliquity (n=7; 12.5%). In 31 (15.9%) patients, measurement discrepancy occurred at diagnostic or prognostic cut-offs. Conclusions-Although maximal LVWT by echocardiography in general measured similar to CMR, discordance because of limitations in echocardiography technique was present in a significant subset of patients. As measurement of LVWT impacts diagnosis and sudden death management, CMR should be considered as part of routine evaluation of all patients with hypertrophic cardiomyopathy. (Circ Cardiovasc Imaging. 2017;10:e006309.
H ypertrophic cardiomyopathy (HCM) is a common genetic heart disorder typically characterized by unexplained, usually asymmetrical left ventricular hypertrophy (LVH). [1] [2] [3] Despite a genetic basis for the disease, the diagnosis of HCM remains clinical and dependent on accurate assessment of left ventricular wall thickness (LVWT). 4, 5 Traditionally, clinicians have relied on echocardiography to document LVH. In fact, the association between degree of LVH and sudden cardiac death (SCD) has been based on measurements of maximum LVWT by echocardiography. [6] [7] [8] Recently, however, cardiac magnetic resonance (CMR) has shown an increased penetrance in clinical practice because of its superior tomographic characterization of cardiac structure and role in SCD risk stratification. 9, 10 Whether measurements of LVWT by echocardiography and CMR are interchangeable has been brought to question. [11] [12] [13] [14] Current American
Heart Association/American College of Cardiology and European Society of Cardiology guidelines do not discriminate between measurements obtained by either imaging modality for clinical diagnosis, and leeway is given for clinical interpretation. 15, 16 Moreover, the HCM SCD risk calculator endorsed by European Society of Cardiology guidelines includes maximal LVWT as measured by echocardiography only. 17 In the present study, we sought to evaluate the incidence of discrepant measurements of maximal LVWT between echocardiography and CMR as obtained from routine clinical practice (as opposed to a core laboratory setting) and to review such cases systematically to determine causes for real-world measurement discrepancies. Left Ventricular Wall Thickness Discrepancy in HCM
Methods

Study Population
Genotyped patients (>18 years old) with diagnosed HCM who underwent imaging by both CMR and echocardiography at Toronto General Hospital within 6 months between January 2008 to March 2016 were included in this study. HCM was defined as demonstrable LVH (≥15 mm) on at least 1 imaging modality in the absence of another disease process capable of producing similar magnitudes of hypertrophy. 16 Patients with a history of septal reduction therapy were excluded. Demographic and cardiac profile data were collected retrospectively. The study was approved by the Research Ethics Board at Toronto General Hospital.
Echocardiography
Echocardiographic images were obtained during routine clinical encounter using standard commercially available 2-dimensional imaging (Philips IE 33) with 2.5-and 3.5-MHz transducers equipped with harmonic imaging. All studies were interpreted by staff cardiologists who had completed level III training in echocardiography. Hypertrophied LV segments were identified from 2-dimensional echocardiographic images according to the American Heart Association 17-segment model. As per institutional protocol, LVWT was measured in the parasternal long-and short-axis views at end diastole using a standard calibration scale. Maximal LVWT was defined as the measurement reported by the echocardiography reader representing the greatest dimension at any site within the LV myocardium.
Cardiac Magnetic Resonance
CMR imaging was performed using a 1.5-or 3-T scanner (Siemens, Erlangen, Germany) as part of routine clinical protocol. Images were obtained using steady-state, free-procession breath-hold cines in 3 long-axis planes and sequential short-axis slices from the atrioventricular ring to the apex. In-plane image resolution for cine was typically 1.2×1.6 mm. CMR images were interpreted by either radiologists or cardiologists with dedicated CMR training. LV endocardial and epicardial borders were planimetered manually in all cine images on the short-axis stack of the entire LV to define the myocardium. Maximal LVWT was defined as the measurement reported by the CMR reader representing the greatest dimension at any site within the LV myocardium at end diastole. LV volume, mass, and ejection fraction were obtained from CMR report and were measured by use of standard volumetric techniques and analyzed with commercially available software (QMASS version 7.4, Medis Inc).
LVWT Discrepancy
We used a cut-off of ≥10% difference in reported measured maximal LVWT between echocardiography and CMR to identify patients with HCM for evaluation of responsible causes. This cut-off, although arbitrary, was felt to be greater than what would be expected from interobserver variability and sufficient to impact clinical diagnosis and SCD risk determination. Once a discrepancy ≥10% was noted, the echocardiographic and CMR images were reviewed side by side by 1 reviewer (W.H.). To help determine cause of discrepancy, LVWT was remeasured with the reviewer blinded to initial reported measurements. These measurements, however, were not included in the discrepancy analysis.
For the purposes of this study, maximal LVWT as assessed by CMR was considered the gold standard. Accordingly, the first step was to determine whether the reported CMR measurements were indeed accurate using both still frame and cine images. In cases where CMR measurement was identified as erroneous, the measurement was analyzed for inappropriate inclusion of right ventricular (RV) and LV trabeculations, as well as papillary structures. Once measurements by CMR were validated, maximal LVWT measurement as assessed by echocardiography was then compared with CMR to determine causes for discrepancy. Cine images from multiple planes and views were used, using tomographic cross-reference lines and locator points to precisely identify and differentiate LV myocardial structures from other structures. This anatomic cross referencing was used to determine the causes accounting for the discrepancies (Figure 1) .
The discrepancies were classified based on whether echocardiography resulted in over-or underestimation of LVWT. When there was overestimation, images were analyzed for inappropriate inclusion of RV myocardium, LV trabeculations, and papillary muscle, as well as imaging plane obliquity. Obliquity was considered when (1) other mechanisms have been excluded, (2) short-axis measurements between echocardiography and CMR were comparable, and (3) the most hypertrophied segment was only demonstrable on the parasternal long-axis view. When there was underestimation, images were analyzed for missed focal hypertrophy and inadequate myocardial segment visualization by echocardiography. All analyses of discrepancy causes were reviewed by a second reviewer with expertise (level III) in both echocardiography and CMR in patients with HCM (R.C.).
Reproducibility
Interobserver and intraobserver variabilities of wall thickness measurements by reviewers were undertaken as a surrogate to validate the reproducibility of discrepancy analysis. Interobserver variability for the measurement of LVWT by echocardiography and CMR was assessed in a subset of 30 randomly selected patients with HCM in the study cohort. Two readers (W.H. and R.C.) independently measured LVWT by echocardiography and CMR without prior knowledge of the clinical data. For intraobserver variability, 1 reader (W.H.) independently measured LVWT by echocardiography and CMR in an identical fashion on 2 occasions (2 months apart) while blinded to the clinical data in a subset of 20 randomly selected patients.
Statistical Analysis
Continuous variables are presented as mean±SD and categorical variables as frequencies or percentages. Continuous variables were tested for normality. Comparisons between discrepant versus nondiscrepant, as well as apical versus nonapical patients, were performed by unpaired Student t test and χ 2 test for continuous and categorical variables, respectively. Bland-Altman model was used to determine measurement agreement. Kappa (κ) coefficient was used to assess intermodal agreement of maximal LVWT location. The validity and reproducibility were evaluated by intraclass correlations. P<0.05 was considered statistically significant. Statistical analysis was performed using STATA 14.0 (StataCorp., 2015) and MedCalc for Windows, version 15.0 (MedCalc Software, Ostend, Belgium).
Results
Study Population
The study included a total of 195 patients. Twenty patients (10.3%) had isolated apical HCM. Baseline characteristics are presented in Table 1 . The mean age of the study cohort was 52.8±15.1 years (range, 18-86 years). The majority of patients were genotype negative (73.8%) and asymptomatic, that is, New York Heart Association I (66.7%). The median time interval between echocardiography and CMR was 41 days (interquartile range, 16-97 days). Ninety-seven (49.7%) patients were identified to have significant discrepancy (≥10%) in measured LVWT. Distribution of patients based on percent discrepancy is summarized in Table 2 . There were no significant differences in baseline characteristics (including age, sex, and body surface area) between patients with and without LVWT discrepancy.
Comparison of Echocardiography and CMR in Entire Cohort
For the entire cohort, mean maximal LVWT measured by echocardiography was similar when compared with CMR (20.6 versus 20.2 mm; P=0.36). By Bland-Altman plot, mean maximal LVWT difference between echocardiography and CMR was 0.5 mm (95% confidence interval [CI], −6.9, 7.8 mm), and there was equal distribution of discrepancy along the full range of measured LVWT ( Figure 2 ). With respect to site of maximal LVWT, echocardiography and CMR identified the same location of maximal hypertrophy in 136 (70.0%) patients.
Apical Versus Nonapical HCM
Mean differences in maximal LVWT between echocardiography and CMR were greater in patients with apical HCM (mean difference=1.7 mm; 95% CI, −6.0, 9.3 mm) as compared with nonapical HCM patients (mean difference=0.3 mm; 95% CI, −6.9, 7.6 mm). Similarly, intermodality agreement for site of maximal hypertrophy was lower in apical HCM patients (κ=0.32; 85% CI, 0.067-0.57) when compared with nonapical HCM patients (κ=0.49; 96% CI, 0.38-0.61). There was a similar prevalence of discrepant measurements of maximal LVWT among apical (n=9; 45.0%) and nonapical HCM patients (n=88; 50.2%) based on a 10% cut-off (P=0.65). However, at higher cut-offs, discrepancies were significantly more prevalent in patients with apical HCM (Table 2) .
Causes of Discrepancy in Measured LVWT
Among the 97 patients who were identified as having measurement differences ≥10% according to clinical reports, we identified 7 patients (7.2%) where the CMR reported measurement was inaccurate. These were because of inappropriate inclusion of RV trabeculations (n=6) and papillary muscle (n=1). All these cases, however, were a result of erroneous interpretation by the CMR reader and were in fact readily identifiable by the reviewer using cine images. In the remaining 90 patients (92.8%), there were true discrepancies between both imaging modalities, and these were a result of either over-or underestimation of maximal LVWT by echocardiography.
Overestimation
In 58 patients (59.8%), echocardiography resulted in overestimation of maximal LVWT. The most common reason was inclusion of RV trabeculations which occurred in 37 patients (38.1%). The remainder of cases was either because of obliquity of imaging plane (n=12; 12.3%) or inclusion of either papillary muscle (n=3; 3.1%), LV trabeculation (n=5; 5.2%), or apical-septal bundle (n=1; 1.0%; Figure 3 ).
Underestimation
In 32 patients (33.0%), echocardiography underestimated maximal LVWT because of an inability to adequately capture the most hypertrophied myocardial segment where it was clearly identified by CMR. In the majority of cases (22 patients; 22.7%), poor acoustic windows and limited myocardial visualization were responsible for failure to capture the most hypertrophied myocardial segment. Among those patients, missed hypertrophy occurred in the anterior wall (n=10), mid anteroseptum (n=6), mid inferoseptum (n=3), anterolateral (n=1), apical septum (n=1), and apical lateral wall (n=1). In the remaining cases (10 patients; 10.3%) of underestimation, myocardial hypertrophy was focal, and although echocardiography correctly identified the corresponding LV wall segment, 
Apical HCM
Among the 20 patients with apical HCM, 9 patients had measurement differences ≥10% in maximal LVWT between echocardiography and CMR. In 6 patients, echocardiography resulted in overestimation of LVWT because of either inclusion of LV trabeculation (n=4) or papillary muscle (n=2). In the remaining 3 patients, echocardiography underestimated LVWT as a result of poor acoustic windows (n=2) or missed focal hypertrophy (n=1; Figure 5 ).
Discrepancies at Clinically Significant Diagnostic and Prognostic Thresholds
Among the entire cohort, 31 patients (15.9%) had differences in measured maximal LVWT ≥10% at diagnostic (15 mm) or prognostic (30 mm) cut-offs. In 7 patients, echocardiography estimated maximal LVWT < 15 mm while CMR measured ≥ 15 mm. In 13 patients, echocardiography estimated maximal LVWT ≥ 15 mm while CMR measured < 15 mm. In 2 patients, echocardiography measured maximal LVWT < 30 mm while CMR measured ≥ 30 mm. In 9 patients, echocardiography measured maximal LVWT ≥ 30 mm while CMR measured <30 mm (Table I in the Data Supplement).
Of these, 16 patients (8.2%) had clinically significant discrepancy wherein measurement differences had potential to affect a patient's diagnosis (6 patients) or prognosis (10 patients; Table 3 ). In 8 patients, maximal LVWT as assessed by echocardiography conferred erroneously a higher risk of SCD. Similarly, because of inaccurate interpretation, reported measurement by CMR in 2 patients suggested high risk. In 1 patient with apical HCM, echocardiography was unable to adequately visualize apical endocardium and in fact had 
Reproducibility of LVWT Measurements
Interobserver variability showed minimal differences in the measurements of maximal LVWT by echocardiography and CMR between the 2 observers (intraclass correlations of 0. 
Discussion
The present study systematically evaluated the incidence and more importantly, the mechanisms for discrepancy in real-world measurements of maximum LVWT between echocardiography and CMR in patients with HCM. We show that despite an acceptable mean difference in maximum LVWT between echocardiography and CMR, significant individual variability exists, and almost half of all patients had ≥10% difference between the 2 modalities. In a small subset of patients, measurement differences were because of erroneous interpretation of wall thickness by CMR reader as opposed to true discrepancy based on imaging technique. The vast majority of discrepant cases, however, were a result of technical limitations of echocardiography wherein 4 primary mechanisms resulted in their occurrence: (1) inaccurate delineation of epicardial/endocardial borders, (2) imaging plane obliquity, (3) poor acoustic windows and shadowing leading to limited visualization of hypertrophied segment, and (4) focal hypertrophy. Moreover, we also identified in a significant number of patients that the adjunctive use of CMR helped establish clinical diagnosis and improve risk stratification for SCD.
Although traditionally echocardiography has been the imaging modality of choice in HCM, the emergence of CMR has increased the scrutiny of echocardiography's reliability for LVWT assessment, particularly in cases where hypertrophy is apical, focal, and involving the anterolateral LV free wall. 9, 12, 14 High spatial resolution, sharp contrast between bright blood and dark myocardium, full tomographic ventricular coverage, and short-axis images derived geometrically perpendicular to the true LV long axis allow measurements of LVWT by CMR to be more precise and accurate. Specifically, LV epicardial/endocardial borders are better delineated, and all hypertrophied segments are visualized without any risk of obliquity. [18] [19] [20] [21] It is for the above reasons that we consider the CMR measurement to be the reference standard for the purpose of this study.
Prior studies have shown LVWT measurements by echocardiography to correlate well with CMR. 11, 13, 22 In a study of 72 patients with HCM comparing LVWT measurements between echocardiography, contrast echocardiography, and CMR, Corona-Villalobos et al 13 found an overall good to excellent correlation with the greatest discrepancies occurring in patients with highest degree of hypertrophy. In addition, they observed that measurements by echocardiography and to a lesser extent contrast echocardiography were consistently higher than those by CMR. 13 However, these results were based on measurements obtained under the scrutiny of research protocol and may not necessarily reflect routine clinical practice. Recently, Bois et al 23 reviewed real-world measurements of maximum LVWT in 618 patients with HCM and found despite an overall good correlation between echocardiography and CMR, there was substantial individual variation and no predilection for discrepancy at extremes of hypertrophy.
Our study confirms the findings of Bois et al 23 but additionally evaluates the mechanisms accounting for discrepancy occurrence. Based on a 10% cut-off (and 20% cut-off, data not shown), we found no differences in baseline patient characteristics, including age, sex, and body surface area between HCM patients with and without LVWT discrepancy, suggesting that differences in measurements were unrelated to patient-specific factors.
Furthermore, when we reviewed the reported measurements by CMR for validation, we determined that in a minority of patients, maximal LVWT was inaccurately overestimated (by the interpreting clinician) either because of inappropriate inclusion of papillary muscle or RV trabeculation (likely the crista supraventricularis). These errors in LVWT measurements were clearly identifiable on cine images and occurred because of misinterpretation by the CMR reader as to where LV myocardium should be delineated, rather than because of the quality of CMR images. In HCM, the crista supraventricularis and papillary muscles are frequently hypertrophied. When deciding where to measure LVWT, use of still frame CMR images alone may be inadequate to delineate the true LV myocardial border with respect to the aforementioned structures. In our study, we found that this can be readily overcome by simultaneous viewing of cine images which typically allows non-LV myocardial structure borders to be better differentiated, thus minimizing potential for LVWT overestimation.
More commonly, measurement discrepancies were caused by over-and underestimations of LVWT by echocardiography. In cases where echocardiography estimates were greater than CMR, we demonstrate 2 clear mechanisms for the discrepancy. The most common reason was inability to adequately delineate true myocardial borders resulting in inadvertent inclusions of RV myocardium, LV trabeculation, apical-septal muscle bundle, and papillary muscle. The remainder of cases were related to obliquity in imaging plane to derive the parasternal long-axis image, something that is impossible to avoid in all patients because of an individual's unique anatomic echocardiographic windows.
However, when echocardiography estimates were less than those accurately measured by CMR, echocardiography universally failed to visualize the true extent of hypertrophy either because hypertrophy was too focal or the maximally hypertrophied myocardial segment was missed because of limited image planes and poor acoustic windows, with the latter accounting for most cases. Notably, similar to Rickers et al, 12 in our cohort, hypertrophy involving the anterolateral LV wall was most commonly to be missed or underestimated.
Moreover, in a subanalysis consisting of apical HCM patients, we show an overall lower agreement between echocardiography and CMR with a larger preponderance of discrepancy at higher discrepancy cut-offs. In the majority of cases, LVWT measurements by echocardiography were overestimated as a result of inclusion of LV and RV trabeculations, as well as displaced papillary muscles. It is noteworthy that in 1 patient, echocardiography had inaccurately suggested that hypertrophy was maximal at the basal septum and raised a question of an apical aneurysm because of poor visualization of apical endocardium. In contrast, on CMR, there was clear apical hypertrophy with no coexisting aneurysm. Furthermore, in another patient, CMR had shown thinning of apical walls compared with a prior CMR which was not detected by echocardiography. Recognition of apical wall thinning in HCM may prompt closer patient surveillance for apical aneurysm detection, which has risk significance for SCD and thromboembolism. 24 Ultimately, clinicians depend on the accurate and reproducible assessments of LVWT in HCM to help establish a clinical diagnosis and to stratify patients as to their risk of SCD and need for intracardiac defibrillator consideration. When we evaluated patients with significant discrepancies at diagnostic (15 mm) and prognostic cut-offs (30 mm), we found in 8% of our entire cohort that applying measurements by 1 imaging modality alone had serious potential for either misdiagnosis or misclassification of SCD risk. Similar to our findings, Bois et al 23 also showed discrepancies implicating SCD risk assessment. The present study did not evaluate clinical outcomes of patients with significant discrepancy. However, in a disease where heritable and fatal consequences are at stake, 8% represents a significant subgroup necessitating efforts to resolve the issue.
The findings in our study have several implications. Measurement discrepancies in LVWT are common, and because patients with HCM are increasingly being referred for CMR evaluation, clinicians are likely to be faced frequently with discrepant maximal LVWT measurements. No patient characteristics or degree of LVH can reliably predict who would be at risk for discrepant measurements. Moreover, whereas inaccurate measurements by CMR were exclusively because of interpreter error and thus can be remedied by improved interpretation skills, those by echocardiography were inherent to the technique itself and effectively can be undetected without CMR comparison. Accordingly, to better assess extent of LV hypertrophy, where possible, we advocate for routine use of CMR in addition to echocardiography in patients with HCM. Echocardiography remains an essential tool for hemodynamic measurements and evaluation of valvular function. 25, 26 However, it must be recognized that CMR imaging may not be feasible for everyone and can be limited by its cost and availability, contraindications, patient claustrophobia, and potential image degradation from arrhythmias. In such cases, based on the mechanisms of discrepancy we have identified, contrast echocardiography may be useful, particularly in patients with apical HCM.
When considering risk of SCD, our study shows that measurements of massive hypertrophy (LVWT ≥ 30 mm) between echocardiography and CMR were not necessarily interchangeable. Such discrepancies can lead to important management dilemmas. Clinicians must consider that although CMR measurements, when interpreted correctly, are more precise compared with echocardiography, studies associating degree of LV hypertrophy to SCD have been based historically on echocardiographic measurements. Until the issue of measurement discrepancy is resolved with outcome data, it is paramount that clinicians use their clinical judgment and discretion when selecting the imaging modality with LVWT measurement that most represents an individual's risk of SCD. Careful consideration of the mechanism for intermodal discrepancy and importantly, other risk factors for SCD should be undertaken.
Limitations
Included patients with HCM were part of our genotyped database. However, in our HCM clinic, patients are sent for genotyping routinely, thus selection bias is unlikely. All data were derived from a single HCM dedicated center, where there is institutional expertise in echocardiography and CMR in patients with HCM. It would not be unexpected that the incidence of discrepant measurements may be even higher in centers with lower HCM patient volumes. In addition, echocardiographic and CMR images were not necessarily obtained on the same day. However, in contrast to measurements of dynamic variables, such as LV outflow tract gradient, we do not expect significant variation in LVWT during a reasonable time frame because it is a static measure that is not volume or load dependent. It would be implausible to observe significant changes in LVWT during the short time period between echocardiography and CMR in this cohort (mean=56±48 days). Furthermore, our analysis of discrepancy was limited to patients who were identified by an arbitrary cut-off of 10% measurement differences.
Conclusions
Discordance between echocardiography and CMR measurements of maximal LVWT is a common phenomenon and can occur because of erroneous myocardial delineation most commonly involving inclusion of RV trabeculation, obliquity of echocardiography planes, and failure to visualize of areas with maximal LV hypertrophy. As errors in measurement by echocardiography are inherent to limitations of technique, routine use of CMR in the evaluation of all patients with HCM should be considered for LVWT assessment to help reduce potential for misdiagnosis and SCD risk misclassification.
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